Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 451 across all filing types
Latest filing 2022-11-23 Call Transcript
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Transcript of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 100% confidence The document is a transcript of an earnings conference call held by Orchid Pharma Limited on November 18, 2022, discussing the company's financial results for the quarter and half year ended September 30, 2022. It includes detailed management commentary on financial performance, capacity, product pipeline, and market outlook, as well as a Q&A session with analysts. The presence of a full transcript of the call, including management and moderator dialogue, confirms this is a Call Transcript (CT) rather than a brief earnings release or presentation. The document length (15,000 characters) and content depth support this classification.
2022-11-23 English
Recording of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a short announcement dated November 18, 2022, addressed to stock exchanges regarding the outcome of an analysts/investors call. It references an investor call held on the same day to discuss un-audited financial results for the quarter and half year ended September 30, 2022. The document provides a link to the audio recording of the call and requests the information be taken on record. The text does not contain actual financial data or detailed financial statements, but rather is an announcement about the availability of the call recording. The document length is only 1621 characters, which is quite short and consistent with an announcement rather than a full report or transcript. According to the classification rules, announcements about calls or their recordings are best classified as Regulatory Filings (RNS) since it does not contain the full transcript or detailed financial data. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2022-11-18 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Investors Presentation Q2 FY23 – Orchid Pharma Limited' and is dated November 18, 2022. It contains detailed financial results for the quarter and half year ended September 30, 2022, including revenue, EBITDA, and other performance highlights. The content includes company overview, management team details, strategy, and growth drivers, typical of an investor presentation. The document length is about 15,000 characters, indicating a full presentation rather than a brief announcement. There is no indication that this is a regulatory filing, certification, or announcement of a report publication. Therefore, the document fits the category of an Investor Presentation (IP).
2022-11-18 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Investors Presentation Q2 FY23 – Orchid Pharma Limited' and is addressed to stock exchanges, indicating it is an official investor communication. It references un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2022. The content includes detailed financial highlights, company overview, management team, strategy, and growth drivers, typical of an investor presentation. The document is about 15,000 characters long, which is consistent with a detailed presentation rather than a brief announcement. There is no indication that this is a full annual or interim report with comprehensive financial statements, nor is it a transcript, audit report, or regulatory filing. Therefore, the document fits the category of an Investor Presentation (IP).
2022-11-18 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings
2022-11-15 English
Newspaper Advertisements
Interim / Quarterly Report Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the publication of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2022. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of quarterly financial results. The document includes the financial results themselves, not just an announcement of their publication. The presence of detailed financial data for a quarter and half year period indicates this is an Interim / Quarterly Report. The document length (15,000 characters) supports that it contains substantive financial data rather than a brief announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2023
2022-11-15 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.